Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 274 entries
Sorted by: Best Match Show Resources per page
Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells.

Oncoscience

Amantini C, Morelli MB, Santoni M, Soriani A, Cardinali C, Farfariello V, Eleuteri AM, Bonfili L, Mozzicafreddo M, Nabissi M, Cascinu S, Santoni G.
PMID: 26097873
Oncoscience. 2015 Mar 23;2(4):395-409. doi: 10.18632/oncoscience.147. eCollection 2015.

Sorafenib, a tyrosine kinase inhibitor, has been demonstrated to exert anti-tumor effects. However, the molecular mechanisms underlying its effects on bladder cancer remain unknown. Here, we evaluated the mechanisms responsible for the sorafenib-induced anti-tumor effects on 5637 and T24...

Cite
Amantini C, Morelli MB, Santoni M, et al. Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells. Oncoscience. 2015;2(4):395-409doi: 10.18632/oncoscience.147.
Amantini, C., Morelli, M. B., Santoni, M., Soriani, A., Cardinali, C., Farfariello, V., Eleuteri, A. M., Bonfili, L., Mozzicafreddo, M., Nabissi, M., Cascinu, S., & Santoni, G. (2015). Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells. Oncoscience, 2(4), 395-409. https://doi.org/10.18632/oncoscience.147
Amantini, Consuelo, et al. "Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells." Oncoscience vol. 2,4 (2015): 395-409. doi: https://doi.org/10.18632/oncoscience.147
Amantini C, Morelli MB, Santoni M, Soriani A, Cardinali C, Farfariello V, Eleuteri AM, Bonfili L, Mozzicafreddo M, Nabissi M, Cascinu S, Santoni G. Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells. Oncoscience. 2015 Mar 23;2(4):395-409. doi: 10.18632/oncoscience.147. eCollection 2015. PMID: 26097873; PMCID: PMC4468325.
Copy Download .nbib Format: NLM
Selective transcriptional regulation by Myc: Experimental design and computational analysis of high-throughput sequencing data.

Data in brief

Pelizzola M, Morelli MJ, Sabò A, Kress TR, de Pretis S, Amati B.
PMID: 26217715
Data Brief. 2015 Feb 12;3:40-6. doi: 10.1016/j.dib.2015.02.003. eCollection 2015 Jun.

The gene expression programs regulated by the Myc transcription factor were evaluated by integrated genome-wide profiling of Myc binding sites, chromatin marks and RNA expression in several biological models. Our results indicate that Myc directly drives selective transcriptional regulation,...

Cite
Pelizzola M, Morelli MJ, Sabò A, et al. Selective transcriptional regulation by Myc: Experimental design and computational analysis of high-throughput sequencing data. Data Brief. 2015;3:40-6doi: 10.1016/j.dib.2015.02.003.
Pelizzola, M., Morelli, M. J., Sabò, A., Kress, T. R., de Pretis, S., & Amati, B. (2015). Selective transcriptional regulation by Myc: Experimental design and computational analysis of high-throughput sequencing data. Data in brief, 340-6. https://doi.org/10.1016/j.dib.2015.02.003
Pelizzola, Mattia, et al. "Selective transcriptional regulation by Myc: Experimental design and computational analysis of high-throughput sequencing data." Data in brief vol. 3 (2015): 40-6. doi: https://doi.org/10.1016/j.dib.2015.02.003
Pelizzola M, Morelli MJ, Sabò A, Kress TR, de Pretis S, Amati B. Selective transcriptional regulation by Myc: Experimental design and computational analysis of high-throughput sequencing data. Data Brief. 2015 Feb 12;3:40-6. doi: 10.1016/j.dib.2015.02.003. eCollection 2015 Jun. PMID: 26217715; PMCID: PMC4510069.
Copy Download .nbib Format: NLM
The Affordable Care Act Insurance Reforms: Where Are We Now, and What's Next?.

Clinical diabetes : a publication of the American Diabetes Association

Borelli MC, Bujanda M, Maier K.
PMID: 26807011
Clin Diabetes. 2016 Jan;34(1):58-64. doi: 10.2337/diaclin.34.1.58.

No abstract available.

Cite
Borelli MC, Bujanda M, Maier K. The Affordable Care Act Insurance Reforms: Where Are We Now, and What's Next?. Clin Diabetes. 2016;34(1):58-64doi: 10.2337/diaclin.34.1.58.
Borelli, M. C., Bujanda, M., & Maier, K. (2016). The Affordable Care Act Insurance Reforms: Where Are We Now, and What's Next?. Clinical diabetes : a publication of the American Diabetes Association, 34(1), 58-64. https://doi.org/10.2337/diaclin.34.1.58
Borelli, M Claire, et al. "The Affordable Care Act Insurance Reforms: Where Are We Now, and What's Next?." Clinical diabetes : a publication of the American Diabetes Association vol. 34,1 (2016): 58-64. doi: https://doi.org/10.2337/diaclin.34.1.58
Borelli MC, Bujanda M, Maier K. The Affordable Care Act Insurance Reforms: Where Are We Now, and What's Next?. Clin Diabetes. 2016 Jan;34(1):58-64. doi: 10.2337/diaclin.34.1.58. PMID: 26807011; PMCID: PMC4714719.
Copy Download .nbib Format: NLM
VITILIGO: IS THERE A TREATMENT THAT WORKS?.

Pediatric dermatology

Morelli JG.
PMID: 10721021
Pediatr Dermatol. 2000 Jan;17(1):75-83. doi: 10.1046/j.1525-1470.2000.01716-15.x.

No abstract available.

Cite
Morelli JG. VITILIGO: IS THERE A TREATMENT THAT WORKS?. Pediatr Dermatol. 2000;17(1):75-83doi: 10.1046/j.1525-1470.2000.01716-15.x.
Morelli, J. G. (2000). VITILIGO: IS THERE A TREATMENT THAT WORKS?. Pediatric dermatology, 17(1), 75-83. https://doi.org/10.1046/j.1525-1470.2000.01716-15.x
Morelli. "VITILIGO: IS THERE A TREATMENT THAT WORKS?." Pediatric dermatology vol. 17,1 (2000): 75-83. doi: https://doi.org/10.1046/j.1525-1470.2000.01716-15.x
Morelli JG. VITILIGO: IS THERE A TREATMENT THAT WORKS?. Pediatr Dermatol. 2000 Jan;17(1):75-83. doi: 10.1046/j.1525-1470.2000.01716-15.x. PMID: 10721021.
Copy Download .nbib Format: NLM
Possible modulatory effect of endogenous islet catecholamines on insulin secretion.

BMC endocrine disorders

Borelli MI, Gagliardino JJ.
PMID: 11696250
BMC Endocr Disord. 2001;1(1):1. doi: 10.1186/1472-6823-1-1.

BACKGROUND: The possible participation of endogenous islet catecholamines (CAs) in the control of insulin secretion was tested. METHODS: Glucose-induced insulin secretion was measured in the presence of 3-Iodo-L-Tyrosine (MIT), a specific inhibitor of tyrosine-hydroxylase activity, in fresh and precultured...

Cite
Borelli MI, Gagliardino JJ. Possible modulatory effect of endogenous islet catecholamines on insulin secretion. BMC Endocr Disord. 2001;1(1):1doi: 10.1186/1472-6823-1-1.
Borelli, M. I., & Gagliardino, J. J. (2001). Possible modulatory effect of endogenous islet catecholamines on insulin secretion. BMC endocrine disorders, 1(1), 1. https://doi.org/10.1186/1472-6823-1-1
Borelli, Maria I, and Gagliardino, Juan J. "Possible modulatory effect of endogenous islet catecholamines on insulin secretion." BMC endocrine disorders vol. 1,1 (2001): 1. doi: https://doi.org/10.1186/1472-6823-1-1
Borelli MI, Gagliardino JJ. Possible modulatory effect of endogenous islet catecholamines on insulin secretion. BMC Endocr Disord. 2001;1(1):1. doi: 10.1186/1472-6823-1-1. PMID: 11696250; PMCID: PMC59668.
Copy Download .nbib Format: NLM
Assessment of the toxic potential of hydrocarbon containing sludges.

Environmental pollution (Barking, Essex : 1987)

Morelli IS, Vecchioli GI, Del Panno MT, Garré MI, Costanza OR, Painceira MT.
PMID: 15091525
Environ Pollut. 1995;89(2):131-5. doi: 10.1016/0269-7491(94)00064-k.

A short-time period microbial toxicity test-battery was used for the investigation of acute toxicity and genotoxicity of five hydrocarbon containing sludges. Four sludges were obtained from a petrochemical industry and the fifth from a petroleum refinery. Some of the...

Cite
Morelli IS, Vecchioli GI, Del Panno MT, et al. Assessment of the toxic potential of hydrocarbon containing sludges. Environ Pollut. 1995;89(2):131-5doi: 10.1016/0269-7491(94)00064-k.
Morelli, I. S., Vecchioli, G. I., Del Panno, M. T., Garré, M. I., Costanza, O. R., & Painceira, M. T. (1995). Assessment of the toxic potential of hydrocarbon containing sludges. Environmental pollution (Barking, Essex : 1987), 89(2), 131-5. https://doi.org/10.1016/0269-7491(94)00064-k
Morelli, I S, et al. "Assessment of the toxic potential of hydrocarbon containing sludges." Environmental pollution (Barking, Essex : 1987) vol. 89,2 (1995): 131-5. doi: https://doi.org/10.1016/0269-7491(94)00064-k
Morelli IS, Vecchioli GI, Del Panno MT, Garré MI, Costanza OR, Painceira MT. Assessment of the toxic potential of hydrocarbon containing sludges. Environ Pollut. 1995;89(2):131-5. doi: 10.1016/0269-7491(94)00064-k. PMID: 15091525.
Copy Download .nbib Format: NLM
Spectrophotometric assay for chloramphenicol and some derivatives in the pure form and in formulations.

Journal of pharmaceutical and biomedical analysis

Morelli B.
PMID: 16867480
J Pharm Biomed Anal. 1987;5(6):577-83. doi: 10.1016/0731-7085(87)80068-7.

A new analytical method for chloramphenicol and its derivatives, chloramphenicol succinate sodium and D-(-)-threo-2-amino-L-[p-nitrophenyl]-1,3-propanediol (chloramphenicol base) in the pure state or in pharmaceutical preparations, is described. The method is based on measuring the blue colour produced by the interaction...

Cite
Morelli B. Spectrophotometric assay for chloramphenicol and some derivatives in the pure form and in formulations. J Pharm Biomed Anal. 1987;5(6):577-83doi: 10.1016/0731-7085(87)80068-7.
Morelli, B. (1987). Spectrophotometric assay for chloramphenicol and some derivatives in the pure form and in formulations. Journal of pharmaceutical and biomedical analysis, 5(6), 577-83. https://doi.org/10.1016/0731-7085(87)80068-7
Morelli, B. "Spectrophotometric assay for chloramphenicol and some derivatives in the pure form and in formulations." Journal of pharmaceutical and biomedical analysis vol. 5,6 (1987): 577-83. doi: https://doi.org/10.1016/0731-7085(87)80068-7
Morelli B. Spectrophotometric assay for chloramphenicol and some derivatives in the pure form and in formulations. J Pharm Biomed Anal. 1987;5(6):577-83. doi: 10.1016/0731-7085(87)80068-7. PMID: 16867480.
Copy Download .nbib Format: NLM
First and second derivative spectrophotometric assay of mixtures of cefuroxime and cephalexin.

Journal of pharmaceutical and biomedical analysis

Morelli B.
PMID: 16867433
J Pharm Biomed Anal. 1988;6(2):199-209. doi: 10.1016/0731-7085(88)80046-3.

No abstract available.

Cite
Morelli B. First and second derivative spectrophotometric assay of mixtures of cefuroxime and cephalexin. J Pharm Biomed Anal. 1988;6(2):199-209doi: 10.1016/0731-7085(88)80046-3.
Morelli, B. (1988). First and second derivative spectrophotometric assay of mixtures of cefuroxime and cephalexin. Journal of pharmaceutical and biomedical analysis, 6(2), 199-209. https://doi.org/10.1016/0731-7085(88)80046-3
Morelli, B. "First and second derivative spectrophotometric assay of mixtures of cefuroxime and cephalexin." Journal of pharmaceutical and biomedical analysis vol. 6,2 (1988): 199-209. doi: https://doi.org/10.1016/0731-7085(88)80046-3
Morelli B. First and second derivative spectrophotometric assay of mixtures of cefuroxime and cephalexin. J Pharm Biomed Anal. 1988;6(2):199-209. doi: 10.1016/0731-7085(88)80046-3. PMID: 16867433.
Copy Download .nbib Format: NLM
A role for the appendix in inflammatory bowel disease? Cut it out.

Gastroenterology

Morelli MS, Zucker SD.
PMID: 15108715
Gastroenterology. 2003 Oct;125(4):1270-2; discussion 1272.

No abstract available.

Cite
Morelli MS, Zucker SD. A role for the appendix in inflammatory bowel disease? Cut it out. Gastroenterology. 2003;125(4):1270-2; discussion 1272
Morelli, M. S., & Zucker, S. D. (2003). A role for the appendix in inflammatory bowel disease? Cut it out. Gastroenterology, 125(4), 1270-2; discussion 1272.
Morelli, Michael S, and Zucker, Stephen D. "A role for the appendix in inflammatory bowel disease? Cut it out." Gastroenterology vol. 125,4 (2003): 1270-2; discussion 1272.
Morelli MS, Zucker SD. A role for the appendix in inflammatory bowel disease? Cut it out. Gastroenterology. 2003 Oct;125(4):1270-2; discussion 1272. PMID: 15108715.
Copy Download .nbib Format: NLM
Role of movement in long-term basal ganglia changes: implications for abnormal motor responses.

Frontiers in computational neuroscience

Simola N, Morelli M, Frazzitta G, Frau L.
PMID: 24167489
Front Comput Neurosci. 2013 Oct 23;7:142. doi: 10.3389/fncom.2013.00142.

Abnormal involuntary movements (AIMs) and dyskinesias elicited by drugs that stimulate dopamine receptors in the basal ganglia are a major issue in the management of Parkinson's disease (PD). Preclinical studies in dopamine-denervated animals have contributed to the modeling of...

Cite
Simola N, Morelli M, Frazzitta G, et al. Role of movement in long-term basal ganglia changes: implications for abnormal motor responses. Front Comput Neurosci. 2013;7:142doi: 10.3389/fncom.2013.00142.
Simola, N., Morelli, M., Frazzitta, G., & Frau, L. (2013). Role of movement in long-term basal ganglia changes: implications for abnormal motor responses. Frontiers in computational neuroscience, 7142. https://doi.org/10.3389/fncom.2013.00142
Simola, Nicola, et al. "Role of movement in long-term basal ganglia changes: implications for abnormal motor responses." Frontiers in computational neuroscience vol. 7 (2013): 142. doi: https://doi.org/10.3389/fncom.2013.00142
Simola N, Morelli M, Frazzitta G, Frau L. Role of movement in long-term basal ganglia changes: implications for abnormal motor responses. Front Comput Neurosci. 2013 Oct 23;7:142. doi: 10.3389/fncom.2013.00142. PMID: 24167489; PMCID: PMC3805948.
Copy Download .nbib Format: NLM
A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease.

Parkinson's disease

Morelli M, Blandini F, Simola N, Hauser RA.
PMID: 22754707
Parkinsons Dis. 2012;2012:489853. doi: 10.1155/2012/489853. Epub 2012 Jun 17.

Dyskinesia, a major complication of treatment of Parkinson's disease (PD), involves two phases: induction, which is responsible for dyskinesia onset, and expression, which underlies its clinical manifestation. The unique cellular and regional distribution of adenosine A(2A) receptors in basal...

Cite
Morelli M, Blandini F, Simola N, et al. A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease. Parkinsons Dis. 2012;2012:489853doi: 10.1155/2012/489853.
Morelli, M., Blandini, F., Simola, N., & Hauser, R. A. (2012). A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease. Parkinson's disease, 2012489853. https://doi.org/10.1155/2012/489853
Morelli, Micaela, et al. "A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease." Parkinson's disease vol. 2012 (2012): 489853. doi: https://doi.org/10.1155/2012/489853
Morelli M, Blandini F, Simola N, Hauser RA. A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease. Parkinsons Dis. 2012;2012:489853. doi: 10.1155/2012/489853. Epub 2012 Jun 17. PMID: 22754707; PMCID: PMC3382949.
Copy Download .nbib Format: NLM
Morelli and Heremans respond.

Physical review letters

Heremans J, Morelli DT.
PMID: 10034481
Phys Rev Lett. 1987 Apr 13;58(15):1587. doi: 10.1103/PhysRevLett.58.1587.

No abstract available.

Cite
Heremans J, Morelli DT. Morelli and Heremans respond. Phys Rev Lett. 1987;58(15):1587doi: 10.1103/PhysRevLett.58.1587.
Heremans, J., & Morelli, D. T. (1987). Morelli and Heremans respond. Physical review letters, 58(15), 1587. https://doi.org/10.1103/PhysRevLett.58.1587
Heremans, and Morelli. "Morelli and Heremans respond." Physical review letters vol. 58,15 (1987): 1587. doi: https://doi.org/10.1103/PhysRevLett.58.1587
Heremans J, Morelli DT. Morelli and Heremans respond. Phys Rev Lett. 1987 Apr 13;58(15):1587. doi: 10.1103/PhysRevLett.58.1587. PMID: 10034481.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 274 entries